The collaboration combines Nucleai's artificial intelligence (AI)-enabled spatial biology technology with Mayo's longitudinally annotated, multimodal data sets, lab services, and clinical diagnostic footprint.

Nucleai and Mayo Clinic will focus on several distinct offerings to support drug development, including biomarker discovery and validation, end-to-end spatial biology testing, and algorithm deployment for clinical trials and diagnostic use.

"By combining Mayo Clinic's extensive multimodal datasets, laboratories, and clinical expertise with Nucleai's advanced AI platform, we can bring scale and impact to the entire precision medicine landscape," Avi Veidman, CEO of Nucleai, said in a statement.

Nucleai, Adlai Nortye collaborate on biomarkers for clinical trials
Artificial intelligence firm Nucleai and biopharmaceutical firm Adlai Nortye on Wednesday announced a strategic partnership aimed at identifying, validating,...

Ultivue enters several partnerships for AI-powered phenomics solutions
Ultivue has entered into multiple partnerships to expand on the use of artificial intelligence (AI) to provide high quality analysis of clinical trial...

Nucleai closes $33M series B financing
Artificial intelligence-powered spatial biology company Nucleai closed a $33 million series B financing round, which it will use to advance its spatial...

Nucleai and Debiopharm team up for cancer drug development
Biomarker discovery company Nucleai will work with Swiss pharmaceutical developer Debiopharm to optimize development of a clinical oncology asset per...